Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
Fang Zhao,1 Bo Yang,2 Juan Wang,1 Rui Zhang,1 Jing Liu,1 Fenglei Yin,1 Weixing Xu,1 Chunyuan He1 1Department of Hematology, Cangzhou Central Hospital, Cangzhou, People’s Republic of China; 2Department of Thoracic Surgery, Cangzhou Central Hospital, Cangzhou, People’s Republic of...
Main Authors: | Zhao F, Yang B, Wang J, Zhang R, Liu J, Yin F, Xu W, He C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-05-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/incidence-and-risk-of-cardiac-toxicities-in-patients-with-relapsed-and-peer-reviewed-article-DDDT |
Similar Items
-
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01) -
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01) -
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
by: Elisabetta Antonioli, et al.
Published: (2023-04-01) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01) -
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
by: Shansa Pranami E. Jayaweera, et al.
Published: (2021-11-01)